To assess that long term administration of (a) n-3 PUFA, (b) rosuvastatin is more effective than corresponding placebo in the reduction of:
Cardiovascular mortality, |
Cardiovascular mortality or hospitalizations for heart failure or for any reason |
Sudden cardiac death |
Hospitalizations for any reason |
Hospitalizations for cardiovascular reasons |
Hospitalizations for congestive heart failure |
Myocardial infarction |
Stroke |
|